Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O’Neil,Andreas L. Birkenfeld,Barbara McGowan,Ofri Mosenzon,Sue D. Pedersen,Sean Wharton+4 more-2018-08-01-The Lancet
778
Chat with Paper
AI Agents for this Paper
No abstract available for this paper.
Chat
Click to start Chat